ChromaDex : May 2022 Investor Presentation

05/23/2022 | 05:58pm EDT

Investor Presentation

Rob Fried

Chief Executive Officer

Kevin Farr

Chief Financial Officer

Nasdaq: CDXC | May 2022

ChromaDex Investment Highlights

Leader in the rapidly growing NAD+ market for healthy aging
Proven and proprietary NAD+ boosting supplement supported by 20 clinical trials
Strong revenue growth (34% CAGR(1)) driven by e-commerce and strong gross margins (61.5% in 2021)
Strategic partnerships to grow global distribution footprint with focus on Asia Pacific region

1. Recent agreement to form Joint Venture to further expand in China
Significant opportunity driven by expanded benefit claims and product innovation

(1) CAGR calculated for the 2017-2021 calendar years period

Proven & Proprietary NAD+ Boosting Supplement

Benefitsof Tru Niagen®:

Patented · Proven · Trusted · Safe

20 published human clinical studies

30+ owned and licensed patents(1)

$85MM+ of third-party research on Niagen®

~$170B in total global addressable vitamins and supplements market, growing 5% annually(2)

Multi award winner

Tru Niagen® is the most efficient way to safely elevate NAD+

*Statements have not been evaluated by FDA	3
(1)	Related to Nicotinamide Riboside (NR).
(2)	ChromaDex estimates. See slide 6 for details.

Steady E-commerce Growth and Strong Gross Margins

Impressive historical revenue growth and significant gross margin expansion

Total 2021 net sales reached $67.4MM with $56.7MM in Tru Niagen® sales. E-commerce represents 62% of the business.

Gross margin increase from 49.4% to 61.5% since strategic pivot

to focus on consumer product, Tru Niagen®

		138%
		CAGR
			34.5	41.8
		27.5

	15.0
1.3
2017	2018	2019	2020	2021

Annual e-commerce net sales

($ millions)

45.0									61.5%		62.0%
						59.5%

40.0					55.7%					52.0%

			50.9%

35.0		49.4%

										42.0%

30.0

25.0											32.0%

20.0						35.3	41.5		22.0%

15.0
				25.8					12.0%
10.0
		16.1
	10.5							2.0%
5.0

0.0											-8.0%
2017	2018	2019	2020	2021

Annual gross profit

($ millions)

Expanding Global Distribution Footprint with Strategic Partners

Key E-Commerce Platforms

Tru Niagen® Sales Mix(1)

Key B2B / Distribution Partners(2)

Key Niagen® Ingredient Partners(3)

Domestic

International

	TruNiagen.com		Amazon
	Amazon		Tmall
	Pro.truniagen.com (HCP)		JD.com

69%		31%

(1)	Based on full year 2021 net sales.	5
(2)	SinoPharm partnership is new, with sales expected in 2022.
(3)	W.R. Grace is an exclusive supplier of Niagen® to ChromaDex.

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Disclaimer

ChromaDex Corp. published this content on 23 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 May 2022 21:57:10 UTC.

CHROMADEX CORPORATION

ChromaDex : May 2022 Investor Presentation

Send by mail :